S. mansoniis a waterborne parasite of humans that causes intestinal schistosomiasis. When it infects the body, it releases various kinds of antigens, including some glycans, for example, the LacdiNAc glycan family, especially fucosylated LacdiNAc (LDNF), and several multiple-fucosylation variants highly targeted in anti-schistosoma responses. LDNF is expressed in the schistosomiasis stage of mammals and mollusks, both glycoproteins and glycolipids in adult worms and eggs express LDNF, and male worms usually express LacdiNAc (LDN) and LDNF on their N-glycan antennae. The LDNF antigen family has emerged as a potential anti-schistosomiasis vaccine and diagnostic candidate. In anti-glycan vaccine development, whole cell and cell membrane preparations are usually applied as immunogens to produce antibodies against specific surface glycans.
Fig.1 The life cycle of S. mansoni. (Wikipedia)
CD BioGlyco provides the appropriate nutritional conditions to culture S. mansoni worms by infecting host animals such as mice or monkeys. Then use methods such as mechanical disruption or liquid nitrogen freezing to crush the collected worms, and use an appropriate buffer (such as phosphate buffer) to extract the antigenic substances.
The extracted antigen of S. mansoni may include other impurities for example nucleic acids or proteins. Therefore, antigen purification is required to remove impurities by gel filtration, centrifugation, ion exchange chromatography, and other methods. Higher antigen concentrations are obtained by concentration.
CD BioGlyco uses specific antibodies or other detection methods, such as ELISA and western blot, to detect the extracted and purified antigens to evaluate the content of the antigens.
In addition, CD BioGlyco also directly provides LDNT glycan sequences synthesis and purification services, which are effective targets for S. mansoni and support the development of vaccines against schistosomiasis. We provide professional S. mansoni antigen-based vaccine development services to meet client needs.
Fig.2 S. mansoniantigen production and purification services. (CD BioGlyco)
CD BioGlyco has a mature Glyco™ Vaccine Development Platform, and we provide high-purity and high-active S. mansoni antigen production and vaccine development services to meet the needs of scientific research. Please feel free to contact us if you would like to inquire about specific production details.
References
